Alembic Pharmaceuticals has announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Fingolimod Capsules, 0.5 mg. This drug is a sphingosine 1-phosphate receptor modulator, indicated for treating relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome and active secondary progressive disease in patients aged 10 years and older. The approved Abbreviated New Drug Application (ANDA) is therapeutically equivalent to Novartis Pharmaceuticals Corporation's Gilenya Capsules, 0.5 mg. The market for Fingolimod Capsules is projected to reach approximately $145 million for the twelve months ending December 2025, according to data from IQVIA. This approval not only broadens Alembic's product offerings but also positions the company competitively in the growing neurology market.